# SCOUT (NCT02637687)

> A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02637687
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Bayer
- Conditions: Solid Tumors Harboring NTRK Fusion
- Interventions: Larotrectinib (Vitrakvi, BAY2757556)
- Enrollment: 154
- Primary outcome: Phase 1: Number of participants in an assigned dose cohort with treatment emergent adverse events (TEAEs) by grade assessed by NCI-CTCAE v 4.03 who experience a DLT
- Primary outcome: Phase 1: Number of participants with TEAEs
- Primary outcome: Phase 1: Severity of TEAEs
- Primary outcome: Phase 2: Overall response rate (ORR) by IRRC

## Indexed commentary on SCOUT so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- 3 posts on X

## Order

Focused, $750 at most (a smaller delivered size costs its own price): https://www.erudio.com/contact?report=scout-nct02637687